期刊文献+

miR-369-3p靶向CTHRC1对宫颈癌细胞顺铂耐药性的影响

Effect of miR-369-3p targeting CTHRC1 on cisplatin resistance of cervical cancer cells
下载PDF
导出
摘要 目的:探讨微小RNA-369-3p(miR-369-3p)是否通过靶向胶原三股螺旋重复蛋白1(CTHRC1)影响宫颈癌细胞顺铂(DDP)耐药性。方法:体外培养人宫颈癌细胞HeLa,采用顺铂梯度暴露法构建顺铂耐药宫颈癌细胞株HeLa/DDP;实验分组:DDP+miR-NC组、DDP+miR-369-3p组、DDP+si-NC组、DDP+si-CTHRC1组、DDP+miR-369-3p+pcDNA组、DDP+miR-369-3p+pcDNA-CTHRC1组;采用MTT法检测细胞增殖抑制率及计算IC_(50)值;qRT-PCR检测miR-369-3p、CTHRC1表达量;Transwell小室实验检测细胞迁移及侵袭;双荧光素酶报告实验验证miR-369-3p、CTHRC1的靶向关系;Western blot检测CTHRC1、CyclinD1、MMP-2、MMP-9、p21表达。结果:与HeLa组比较,HeLa/DDP组细胞增殖抑制率、miR-369-3p的表达水平显著降低(P<0.05),IC_(50)值、CTHRC1 mRNA及蛋白水平显著升高(P<0.05);HeLa/DDP细胞转染miR-369-3p mimics或转染si-CTHRC1后,细胞增殖抑制率、p21蛋白水平显著升高(P<0.05),迁移细胞数、侵袭细胞数显著减少(P<0.05),CyclinD1、MMP-2、MMP-9蛋白水平显著降低(P<0.05);双荧光素酶报告实验证实miR-369-3p可靶向结合CTHRC1;CTHRC1过表达可明显逆转miR-369-3p过表达对细胞增殖、迁移、侵袭及顺铂耐药性的作用。结论:miR-369-3p过表达可能通过下调CTHRC1表达抑制HeLa/DDP细胞增殖、迁移及侵袭从而逆转宫颈癌细胞顺铂耐药性。 Objective:To investigate whether miR-369-3p affects the resistance of cervical cancer cell cisplatin(DDP)by targeting CTHRC1.Methods:Human cervical cancer cell HeLa was cultured in vitro,and cisplatin-resistant cervical cancer cell line HeLa/DDP was constructed by cisplatin gradient exposure method.Experimental grouping:DDP miR-NC group,DDP miR-369-3p group,DDP si-NC group,DDP si-CTHRC1 group,DDP miR-369-3p pcDNA group,DDP miR-369-3p pcDNA-CTHRC1 group.MTT method was used to detect cell proliferation inhibition rate and calculated cisplatin IC50 value.qRT-PCR was used to detect expression levels of miR-369-3p and CTHRC1.Transwell cell test was used to detect cell migration and invasion.Dual luciferase report experiment verified the targeting relationship between miR-369-3p and CTHRC1.Western blot was used to detect expression levels of CTHRC1,CyclinD1,MMP-2,MMP-9 and p21.Results:Compared with HeLa group,cell proliferation inhibition rate and expression level of miR-369-3p in HeLa/DDP group were significantly reduced(P<0.05),and the IC_(50) value,expression of CTHRC1 mRNA and protein level of CTHRC1 were significantly increased(P<0.05).After HeLa/DDP cells were transfected with miR-369-3p mimics or si-CTHRC1,the cell proliferation inhibition rate and protein level of p21 were significantly increased(P<0.05),and the number of migrating cells and invading cells were significantly reduced(P<0.05),protein levels of CyclinD1,MMP-2,MMP-9 were significantly reduced(P<0.05).Dual luciferase report experiment confirmed that miR-369-3p could target to bind to CTHRC1.CTHRC1 overexpression could significantly reverse the effects of miR-369-3p overexpression on cell proliferation,migration,invasion and cisplatin resistance.Conclusion:Overexpression of miR-369-3p may reverse the proliferation,migration and invasion of HeLa/DDP cells by down-regulating the expression of CTHRC1 to reverse the resistance of cervical cancer cells to cisplatin.
作者 卫雅娴 李振华 曹彦君 王皓洁 伊诺 WEI Ya-Xian;LI Zhen-Hua;CAO Yan-Jun;WANG Hao-Jie;YI Nuo(Department of Obstetrics and Gynecology,Beijing Ditan Hospital,Capital Medical University,Beijing 100000,China)
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2021年第17期2121-2125,共5页 Chinese Journal of Immunology
关键词 miR-369-3p CTHRC1 宫颈癌 顺铂 耐药性 miR-369-3p CTHRC1 Cervical cancer Cisplatin Drug resistance
  • 相关文献

参考文献8

二级参考文献52

  • 1段纪俊,陈万青,张思维.中国恶性肿瘤死亡率的国际比较[J].中国社会医学杂志,2009,26(6):377-378. 被引量:46
  • 2刘秀芳,王炳胜,熊正文,李宏伟.微血管密度及增殖细胞核抗原表达与宫颈癌放射敏感性的关系初探[J].中国肿瘤临床与康复,2005,12(2):100-102. 被引量:5
  • 3柳萌,杨迪生.顺铂耐药机制的研究进展[J].现代中西医结合杂志,2007,16(6):856-858. 被引量:10
  • 4Bray F, Parkin DM, Evaluation of data quality in the cancer registry: Principles and methods. Part I : Comparability, validity and timeliness [J]. Eur J Cancer, 2009, 45(5): 747-755.
  • 5Curado MP, Edwards B, Shin HR et al. Cancer incidence in five conti- nents, Vol. IX. IARC scientific publications No. 160[M]. Lyon: IARC, 2007.
  • 6Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IAtlC technical report No.19[M]. Lyon: IARC. 1994.
  • 7Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005.
  • 8Felay J. The IARCcrgTools program [CP/OL]. http://www.iaer.com.fr/iarc- crgtools.htm, 2006.
  • 9全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 10杨艳,于廷和.ERCC1与顺铂耐药的研究进展[J].肿瘤,2007,27(12):1008-1009. 被引量:10

共引文献365

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部